TY  - JOUR
TI  - Evaluation of the effectiveness of drug-eluting transarterial  chemoebolization in hepatocellular carcinoma
AB  - Background and Aim: Transarterial Chemoembolization (TACE) thera py is currently considered as first option therapy in the intermediate stage  HCC. The purpose of our study is to assess the efficacy and prognostic  factors related to the DEB- TACE therapy. Materials and Methods: The data from 133 patients with unresecetable  HCC who were treated with DEB-TACE and followed between January  2011-March 2018 were retrospectively evaluated. To assess the efficacy  of therapy, control imagings were performed at 30th and 90th days after  the procedure. Response rates, survival outcomes, and prognostic factors  were investigated. Results: According to the Barcelona staging system, 16 patients (13%)  were in the early stage, 58 patients (48%) were in the intermediate stage  and 48 patients (39%) were in the advanced stage. There were complete  response (CR) in 20 patients (17%), partial response (PR) in 36 patients  (32%), stable disease (SD) in 24 patients (21%) and progressed disease  (PD) in 35 (30%) patients. Median follow-up time was 14 months (range  1-77 months). Median PFS and OS were 4 months and 11 months, re spectively. In multivariate analysis, posttreatment AFP ≥400 ng/ml was  found to be an independent prognostic factor on both PFS and OS. Child Pugh classification and tumor size >7 cm were independent prognostic  factors on OS. Conclusion: DEB-TACE is effective and a tolerable treatment method  for unresectable HCC patients.
AU  - Baltacıoğlu, Feyyaz
AU  - Kani, Haluk Tarik
AU  - ozdogan, osman
AU  - mutis alan, Aydan
AU  - Alan, Ozkan
AU  - Asadov, Ruslan
AU  - Demirtas, Coskun
AU  - Yumuk, Perran Fulden
AU  - Dilber, Feyza
PY  - 2023
JO  - Hepatology forum
VL  - 4
IS  - 2
SN  - 1307-5888
SP  - 53
EP  - 60
DB  - TRDizin
UR  - http://search/yayin/detay/1178897
ER  -